Pfizer execs to stand trial for cover-up of drug trial results

Monday, April 02, 2012 by: Ethan A. Huff, staff writer
Tags: Pfizer, executives, cover-up

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
CDC issues flu vaccine apology: this year's vaccine doesn't work!
The five biggest lies about Ebola being pushed by government and mass media
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
Tetanus vaccines found spiked with sterilization chemical to carry out race-based genocide against Africans
Biologist explains how marijuana causes tumor cells to commit suicide
Companies begin planting microchips under employees' skin
The best way to help your body protect itself against Ebola (or any virus or bacteria)
NJ cops bust teenagers shoveling snow without a permit
Russia throws down the gauntlet: energy supply to Europe cut off; petrodollar abandoned as currency war escalates
McDonald's in global profit free fall as people everywhere increasingly reject chemically-altered toxic fast food
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
Top ten things you need to do NOW to protect yourself from an uncontrolled Ebola outbreak
Chemotherapy kills cancer patients faster than no treatment at all
FDA targets Dr. Bronner's Magic Soaps for sharing health benefits of coconut oil
U2's Bono partners with Monsanto to destroy African agriculture with GMOs
Why flu shots are the greatest medical fraud in history
Governments seize colloidal silver being used to treat Ebola patients, says advocate
Flu vaccine kills 13 in Italy; death toll rises

(NaturalNews) Four former executives at Pfizer Inc., the world's largest drug company. -- Henry McKinnell, John LaMattina, Karen Katen, Joseph Feczko -- as well as Gail Cawkwell, Pfizer's current Vice President of Medical Affairs, will all face trial for allegedly concealing the unfavorable results of drug trials involving Celebrex and Bextra. Courthouse News Service (CNS) reports that U.S. District Judge Laura Taylor Swain has denied requests made by defendants to dismiss the case, which means all five individuals will be held to account for their actions.

The securities class-action lawsuit, which was filed by the Teachers Retirement System of Louisiana (TRSL) on behalf of Pfizer stockholders, alleges that the five defendants violated federal securities laws by concealing the results of studies involving Celebrex, a COX-2 inhibiting anti-inflammatory drug, and Bextra, a non-steroidal anti-inflammatory drug (NSAID) that was pulled from the market in 2005.

According to the suit, the five defendants made misleading statements in their public filings about the drug trials, and also omitted important information that exposed both Celebrex and Bextra as being dangerous. And despite numerous attempts by Pfizer and the defendants to have the case dismissed or reconsidered, the case will now proceed as intended following Judge Swain's ruling that the plaintiffs provide sufficient evidence to show that Celebrex and Bextra are "linked to adverse cardiovascular events to a statistically significant degree, and that these results were known to Defendants."

Because of its class-action status, the lawsuit will also potentially address a number of other lawsuits against Pfizer as well, since it has now been revealed that Celebrex, which is still on the market, has been known to cause heart problems since at least as early as 2004. If the plaintiffs are successful in winning their case, Pfizer shareholders who purchased stock between October 31, 2000, and October 19, 2005, will be covered.

"Over the past seven years, this court has become familiar with both the parties to and the subject matter of this action, and so believes that concentrating this litigation in this forum would promote judicial economy," wrote Judge Swain in her ruling.

Just prior to the ruling, Pfizer actually ended a post-approval safety study of Celebrex due to difficulty finding patients willing to enroll in it. Though the company was initially required by the U.S. Food and Drug Administration (FDA) to conduct such a study, the regulatory agency ended up deciding to simply let Pfizer off the hook rather than hold it accountable to these requirements (

Sources for this article include:

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...


Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of, the internet's No. 1 natural health news site. (Source:

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.